Irwin Naturals reports Q2 EPS ($1.57) vs. 0c last year

Reports Q2 revenue $22.1M vs. $21.8M last year. Sean Sand, CFO, stated, “During the first half of 2023, we successfully launched our branded licensing initiative in our cannabis sector. Sales have exceeded our expectations and we look forward continuing our licensing efforts in the space. We also continued to expand our mental health footprint through the acquisition of an industry leading marketing and patient acquisition platform, Ketamine Media, enabling greater treatment availability and market expansion.”